Replies to post #130897 on Biotech Values

[eawolfie]

I don't think that they consider the data meaningless. It's just not enough to prove the desired utility of cabo. I own exel but I think that jq's assessment is absolutely reasonable.

[mcbio]

I would like certainty Cabo but we do not have it. We do have EXEL at $4.40.

Exactly. If we had certainty, you can bet EXEL wouldn't be at $4.40. It's all about the risk-reward. Given what we know on cabo so far, I'd be willing to take a gamble on EXEL at $4.40. (I have no position currently.)

[iwfal]

EXEL

So we have more pain data that is not meaningful and more extraordinary bone resolution data whose utility in predicting outcomes is unknown. In other words, more of the same.

In your sarcasm you are missing our point - e.g how does this elucidate the chances of success for 306? How can you tell from this data what to expect from placebo in 306? ...

[vinmantoo]

zipjet,

Both jq1234 and Ifwal have expressed the situation regarding Cabo quite well in my view. Jq hit the nail on the head. We need to see a correlation between bone scan resolution and pain reduction, at leads to some degree. It doesn't have to be perfect because one can could understand that in some patients, greater pain reductions could occur with less pronounced bone scan resolution.

You seem to be a bit agitated by these discussions. As Don Corleone said in the Godfather, "it's not personal, it's just business". We are getting more data, and that is a good thing for investors as one can better assess prospects for Cabo. If anything has become clear, it is that the FDA isn't going to accept bone scan resolution as any sort of proof of efficacy.